 NORTH BRUNSWICK, N.J., Dec. 05, 2022 GLOBE NEWSWIRE BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory diseases based on a portfolio built around gelsolin technology, announces a new article on its novel host-directed approach. A Pioneering Biotech Promises to Revolutionize Medicine with a Human Protein that Boosts the Bodys Immune System. ... The post BioAegis Therapeutics Highlights Recent Article on its Novel Host-Directed Protein, Plas... 